Abstract:e14006 Background: Radiation necrosis (RN) is post-radiation complication that leads to increased permeability and disruption of the blood brain barrier (BBB). This in turn leads to a pro-inflammatory state and an increased production of vascular-endothelial growth factor (VEGF). Bevacizumab is a monoclonal antibody against VEGF and is a potential treatment for RN. The objective of the study is to assess effectiveness of bevacizumab (BEV) for the treatment of brain RN in adults. Methods: Retrospective chart review of 22 patients with various solid malignancies including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), metastatic melanoma and breast cancer with clinical or radiographic diagnosis of RN seen at Memorial Cancer Institute (MCI) in a 3-year period, from January 1 st , 2019 to January 1 st , 2023. Radiation doses ranged from 18-24 Gy (single fraction) or 24-27 Gy (3-fraction) for radiosurgery and 30-37.5 Gy for whole brain radiotherapy. Patients were identified that developed RN and VEGF inhibitors were subsequently given to assess effectiveness in the treatment of the condition. We evaluated the dose, frequency, number of treatments received, adverse effects and therapeutic benefits of BEV. Therapeutic benefit was defined as patients that received bevacizumab had a radiological and clinical improvement of the RN (clinical benefit). Brain imaging with MRI or PET/CT scan was completed both pre and post treatment to evaluate efficacy of treatment. Patients were initially given 4 cycles with a subsequent 4 more cycles if it was beneficial and tolerated treatment. Results: 22 patients were included in the study, 9 were males (41%) and median age 66 (range 31-81). 91% (20/22) had a diagnosis of lung cancer. 1 patient had a diagnosis of SCLC, while 19 were diagnosed with NSCLC. The study had a good representation of different races including Non-Hispanic Whites 7 (32%), Hispanics 10 (45%), Blacks 13% (3) and Asians 10% (2). Over 95% (21/22) of patients achieved a clinical benefit, while one patient did not (5%). Patients experienced improvement in cognitive function, headaches, dizziness, weakness, and other symptoms with BEV. MRIs showed improvement in edema and a reduction/stabilization of brain lesions. The most frequent dosing regimen used was BEV 10 mg/kg every two weeks. The median number of cycles given was 4 cycles (1-12). The most common adverse events were hypertension, minor nose bleeding, an occasional protein found in urine. There were no severe AEs or discontinuation of therapy with bevacizumab. Conclusions: This study demonstrated treatment with BEV 10 mg/kg every two weeks for a total of 12 cycles is well tolerated and has potential clinical benefit in RN in lung cancer patients with CNS metastasis. The therapeutic effects of VEGF inhibitors were seen in our small population study but warrants further investigation in a larger population study.

Treatment Of Brain Radiation Necrosis With Mouse-Nerve Growth Factor: A Phase Ii Trial

Mouse nerve growth factor in the treatment of radiation-induced cerebral necrosis

Treatment of Cerebral Radiation Necrosis with Nerve Growth Factor: A Prospective, Randomized, Controlled Phase II Study.

~1H-MRS study on radiation-induced injury of the brain in early acute reaction stage after nasopharyngeal carcinoma radiotherapy

The preventive and therapeutic effect of repetitive transcranial magnetic stimulation on radiation-induced brain injury in mice

Bevacizumab for the Treatment of Gammaknife Radiosurgery-Induced Brain Radiation Necrosis

The Diagnostic Value of Contrast-Enhanced MRI in the Diagnosis of Radiation-Induced Cerebral Injury Following Radiotherapy for Nasopharyngeal Carcinoma

Phase I/II Trial Evaluating Carbon-Ion Radiotherapy for Salvage Treatment of Locally Recurrent Nasopharyngeal Carcinoma

Dynamic MRI Follow-Up of Radiation Encephalopathy in the Temporal Lobe Following Nasopharyngeal Carcinoma Radiotherapy

Outcomes with bevacizumab for radiation induced-brain necrosis.

Long-Term Relief of Cerebral Radiation Necrosis Treated with Low-Dose Bevacizumab - a Report of 2 Cases

Mouse nerve growth factor promotes neurological recovery in patients with acute intracerebral hemorrhage: A proof-of-concept study.

Radiation-induced Gray Matter Atrophy in Patients with Nasopharyngeal Carcinoma after Intensity Modulated Radiotherapy: a MRI Magnetic Resonance Imaging Voxel-Based Morphometry Study.

Rodent Model of Brain Radionecrosis Using Clinical LINAC-Based Stereotactic Radiosurgery

Mouse Nerve Growth Factor Injection and Progression Rate in Patients With Amyotrophic Lateral Sclerosis: An Observational Study

Intranasal Delivery of Nerve Growth Factor to Protect the Central Nervous System Against Acute Cerebral Infarction.

Nuclear Magnetic Resonance Treatment Induces ßNGF Release from Schwann Cells and Enhances the Neurite Growth of Dorsal Root Ganglion Neurons In Vitro

Neuroprotective Effect of Intranasal Administration of Nerve Growth Factor in the Mouse MPTP Model of Parkinson's Disease

Combination Therapy with Intranasal Ngf and Electroacupuncture Enhanced Cell Proliferation and Survival in Rats after Stroke

Unlocking the Potential of Ultra-High Dose Fractionated Radiation for Effective Treatment of Glioblastoma in Mice

Comprehensive Treatment of Radiation-Induced Lower Cranial Neuropathy in Patients with Nasopharyngcal Carcinoma: a Clinical Analysis